Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy transfer assays. The disclosure comes as the U.S.-based biotechnology firm advances EB-003 through IND-enabling studies with the stated goal of developing a non-hallucinogenic neuroplastogenic therapy for depression and anxiety.
